McGray, A. J. R.
Eppolito, C.
Miliotto, A.
Singel, K. L.
Stephenson, K.
Lugade, A.
Segal, B. H.
Keler, T.
Webster, G.
Lichty, B.
Kozbor, D.
Odunsi, K. http://orcid.org/0000-0002-4444-7651
Funding for this research was provided by:
Ovarian Cancer Research Fund (326870)
Roswell Park Cancer Institute
National Institutes of Health (P50CA159981-01A1, UO1 CA233085-01A1, R01CA188900, P30CA016056, R03CA223623)
Article History
Received: 24 November 2020
Accepted: 31 March 2021
First Online: 20 April 2021
Declarations
:
: K Stephenson is an employee of Turnstone Biologics, who hold IP for Maraba Virus. T Keler is the Founder, Executive Vice President, and Chief Scientific Officer of Celldex Therapeutics, who provided the anti-CD27 antibody for these studies. G Webster is the Chief Scientific Officer of Innate Immunotherapeutics, who hold IP for MIS416. B Lichty is an inventor and shareholder of Turnstone Biologics, who hold IP for Maraba Virus. K Odunsi received research funding from Astra Zeneca and Tessaro; and is a co-founder of Tactiva Therapeutics. All other authors have no financial conflicts of interest to disclose
: For animal studies, all performed experiments and procedures were reviewed and approved by the Roswell Park IACUC prior to conducting experiments. For experiments involving human tumor specimens, samples were received in the laboratory from Roswell Park tissue procurement under approved protocol I215512 which allows experimental use of patient tissue specimens for research.
Free to read: This content has been made available to all.